Literature DB >> 17497267

Acute pharmacotherapy of migraine, tension-type headache, and cluster headache.

Peer Tfelt-Hansen1.   

Abstract

In most migraine patients acute therapy is needed. Migraine can be treated either with specific drugs, the triptans and ergot alkaloids, or with NSAIDs. Triptans are a major step foreward in migraine therapy. The therapeutic gain for headache relief is 50% for subcutaneous sumatriptan whereas it is 30-40% for most oral triptans. After oral triptans sustained pain free is only 30%. There is thus still ample room for improvement of acute therapy in migraine. For tension-type headache there is no specific therapy and it is treated with NSAIDs. Only 17-32% become pain free after these drugs. For attacks of cluster headache oxygen and subcutaneous sumatriptan can be used. Intranasal triptans can be an alternative.

Entities:  

Mesh:

Year:  2007        PMID: 17497267      PMCID: PMC3476138          DOI: 10.1007/s10194-007-0373-z

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  5 in total

1.  Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium.

Authors:  Luigi Alberto Pini; Enrico Del Bene; Giorgio Zanchin; Paola Sarchielli; Girolamo Di Trapani; Maria Pia Prudenzano; Giovanni LaPegna; Lidia Savi; Giorgio Di Loreto; Paolo Dionisio; Franco Granella
Journal:  J Headache Pain       Date:  2008-09-25       Impact factor: 7.277

2.  Update on the therapy of the trigeminal autonomic cephalalgias.

Authors:  Marc E Lenaerts
Journal:  Curr Treat Options Neurol       Date:  2008-01       Impact factor: 3.598

Review 3.  Future drugs for migraine.

Authors:  Ivano Farinelli; Sergio De Filippis; Gabriella Coloprisco; Serena Missori; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2009-06-24       Impact factor: 3.397

4.  Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study.

Authors:  Luigi Alberto Pini; Simona Guerzoni; Michela Cainazzo; Michela Ciccarese; Maria Pia Prudenzano; Paolo Livrea
Journal:  J Headache Pain       Date:  2012-10-02       Impact factor: 7.277

Review 5.  Genetics of migraine and pharmacogenomics: some considerations.

Authors:  Maria Piane; Patrizia Lulli; Ivano Farinelli; Simona Simeoni; Sergio De Filippis; Francesca Romana Patacchioli; Paolo Martelletti
Journal:  J Headache Pain       Date:  2007-12-05       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.